semaglutide cardiovascular outcomes news 2025 and by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial Oral Semaglutide and Cardiovascular Outcomes

Patients on chemotherapy should avoid supplementation without oncologist approval

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist, which means it mimics a hormone your body naturally produces to regulate appetite and blood sugar

Once they have been on the 2.4mg dose for 4 weeks, they can titrate up to the new dose of 7.2mg The official Wegovy dosing schedule recommended by clinicians is as follows: If the user is taking the 2.4 mg dose and is happy with their current progress, or isn't noticing a plateau in their weight loss, they can choose to remain on this dose rather than increase to 7.2 mg

B.RizkallaG.WangH.et al (1999)

In The Atlantic , Sarah Zhang called them powerful modulators of appetite, acting not only through the gut but on the brain itself

Fertility and Sterility, 82 (2), S228